Piperazine, piperidine and tetrahydropyridine derivatives and their pharmaceutical use
Novel piperazine, piperidine and tetrahydropyridine derivatives comprising a dibenzofurane moiety are provided herein, as well as pharmaceutical compositions comprising same and therapeutic uses thereof.
1. A compound of the general formula Id or the general formula Ie:
wherein:
R 1 , R 2 and R 3 are independently selected from the group consisting of C1-C5 alkyl, —OH, —SH, halogen, alkoxy, NO 2 , and —CN;
m is 0, 1, 2, 3, 4 or 5;
n is 0, 1, 2 or 3; and
p is 0, 1, 2, 3 or 4.
2. A compound according to claim 1 , wherein m is 0, 1, 2 or 3, and R 1 is selected from the group consisting of hydroxy, alkoxy, halogen and cyano.
3. A compound according to claim 1 , wherein R 1 is hydroxy.
4. A compound according to claim 1 , wherein m is 1.
5. A compound according to claim 1 , wherein n is 0 and p is 0.
6. A pharmaceutical composition comprising a compound as defined in claim 1 in combination with one or more pharmaceutically acceptable carriers.
7. A method for treating CNS dyskinesia in mammals, comprising administering to said mammal a therapeutically effective amount of the compound defined in claim 1 .
8. A compound of formula I:
wherein:
Y 1 and Y 2 are independently CH, C(R 1 ) or N;
X is CH or C, with the proviso that when X is C, then the broken line represents a chemical bond;
R 1 , R 2 and R 3 are independently selected from the group consisting of C1-C5 alkyl, —OH, —SH, halogen, alkoxy, NO 2 , and —CN;
m is 0, 1, 2, 3, 4 or 5;
n is 0, 1, 2 or 3; and
p is 0, 1, 2, 3 or 4.
9. A compound according to claim 8 , having the formulas Id or Ie:
10. A compound according to claim 8 , wherein m is 0, 1, 2 or 3, and R 1 is selected from the group consisting of hydroxy, alkoxy, halogen and cyano.
11. A compound according to claim 8 , wherein R 1 is hydroxy.
12. A compound according to claim 8 , wherein m is 1.
13. A compound according to claim 8 , wherein n is 0 and p is 0.
14. A pharmaceutical composition comprising a compound as defined in claim 8 in combination with one or more pharmaceutically acceptable carriers.
15. A method for treating CNS dyskinesia in mammals, comprising administering to said mammal a therapeutically effective amount of the compound defined in claim 8 .